Bicycle Therapeutics (BCYC) Construction in Progress (2022 - 2023)
Bicycle Therapeutics' (BCYC) quarterly Construction in Progress came in at $400000.0 in Q2 2023, down 82.61% on a QoQ basis from $2.3 million in Q4 2022.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Construction in Progress (2022 - 2023) Analysis & Trends
Bicycle Therapeutics (BCYC) has 2 years of Construction in Progress data on file, last reported at $400000.0 in Q2 2023.
- Quarterly Construction in Progress changed N/A year-over-year to $400000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $400000.0 (changed N/A YoY) and the FY2022 annual result came in at $2.3 million, changed N/A from the prior year.
- Construction in Progress fell to $400000.0 in Q2 2023, from $2.3 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $2.3 million in Q4 2022 to a low of $400000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 152.67 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | - |